Credit Agricole’s Apogee Therapeutics APGE Stock Holding History

Credit Agricole’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,057	Closed	-$1.21K	–	1285
2024 Q3	$1.21K	Buy	+2,057	New	+$98.6K	﹤0.01%	1258

Other funds holding APGE

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Credit Agricole's APGE Position: Q4 2024 in Review

Credit Agricole sold out of Apogee Therapeutics (APGE) in Q4 2024, closing a stake of 2,057 shares — an estimated $1.21K sold.

Credit Agricole first reported a position in APGE in Q3 2024 and held it in 1 quarter. The position peaked at $1.21K in Q3 2024. 157 funds tracked by Wall St. Rank hold APGE as of Q4 2024.

Credit Agricole reported no remaining Apogee Therapeutics position as of Q4 2024 after selling out during the quarter.
Credit Agricole sold 2,057 Apogee Therapeutics shares in Q4 2024, an estimated $1.21K.
Credit Agricole first reported a position in Apogee Therapeutics in Q3 2024 and held it in 1 quarter.
Credit Agricole's Apogee Therapeutics position peaked at $1.21K in Q3 2024.
157 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2024.

Based on Credit Agricole's 13F filing for Q4 2024, filed 14 Feb 2025.